{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:28:14Z","timestamp":1769070494612,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,6]]},"DOI":"10.7759\/cureus.46568","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T09:43:01Z","timestamp":1696585381000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men"],"prefix":"10.7759","author":[{"given":"Sandeep","family":"Sattur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay","family":"Talathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geetanjali","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehnaz","family":"Arsiwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rickson","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhiraj","family":"Dhoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14537","article-title":"Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics","volume":"20","author":"Nestor MS","year":"2021","unstructured":"Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021, 20:3759-81. 10.1111\/jocd.14537","journal-title":"J Cosmet Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00374-y","article-title":"Comparative study to evaluate tolerability of topical 5% minoxidil novel formulation and alcohol-based conventional solutions in treatment of androgenetic alopecia in indian men: randomized double-blind study","volume":"10","author":"Sarkar R","year":"2020","unstructured":"Sarkar R, Vartak S, Acharya S, Kursam NK, Mane A, Mehta S, Charugulla SN. Comparative study to evaluate tolerability of topical 5% minoxidil novel formulation and alcohol-based conventional solutions in treatment of androgenetic alopecia in indian men: randomized double-blind study. Dermatol Ther (Heidelb). 2020, 10:469-79. 10.1007\/s13555-020-00374-y","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.054","article-title":"The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis","volume":"77","author":"Adil A","year":"2017","unstructured":"Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017, 77:136-141.e5. 10.1016\/j.jaad.2017.02.054","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.012","article-title":"A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men","volume":"57","author":"Olsen EA","year":"2007","unstructured":"Olsen EA, Whiting D, Bergfeld W, et al.. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007, 57:767-74. 10.1016\/j.jaad.2007.04.012","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13630","article-title":"Novel \"After Minoxidil\" spray improves topical minoxidil compliance and hair style manageability","volume":"19","author":"Kovacevic M","year":"2020","unstructured":"Kovacevic M, McCoy J, Shapiro J, et al.. Novel \"After Minoxidil\" spray improves topical minoxidil compliance and hair style manageability. J Cosmet Dermatol. 2020, 19:2647-9. 10.1111\/jocd.13630","journal-title":"J Cosmet Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14299","article-title":"SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth","volume":"21","author":"Dhurat R","year":"2022","unstructured":"Dhurat R, Daruwalla S, Pai S, et al.. SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. J Cosmet Dermatol. 2022, 21:343-6. 10.1111\/jocd.14299","journal-title":"J Cosmet Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/1061186X.2010.483516","article-title":"Transcutol containing vesicles for topical delivery of minoxidil","volume":"19","author":"Mura S","year":"2011","unstructured":"Mura S, Manconi M, Valenti D, Sinico C, Vila AO, Fadda AM. Transcutol containing vesicles for topical delivery of minoxidil. J Drug Target. 2011, 19:189-96. 10.3109\/1061186X.2010.483516","journal-title":"J Drug Target"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/jrptps.JRPTPS_25_21","article-title":"A randomized, double-blind controlled clinical study to evaluate the efficacy and safety of minoxidil topical 2% nanosuspension with aqueous base in the treatment of androgenetic alopecia areata","volume":"10","author":"Mirzaeei S","year":"2021","unstructured":"Mirzaeei S, Barfar A, Mehrandish S, Ebrahimi A. A randomized, double-blind controlled clinical study to evaluate the efficacy and safety of minoxidil topical 2% nanosuspension with aqueous base in the treatment of androgenetic alopecia areata. J Rep Pharma Sci. 2021, 10:279-86. 10.4103\/jrptps.JRPTPS_25_21","journal-title":"J Rep Pharma Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.11648\/j.ijcda.20180401.12","article-title":"Dermoscopy is the crucial step for proper outcome prospection when treating androgenetic alopecia with the Regenera\u00ae protocol: a score proposal","volume":"4","author":"Pinto H","year":"2018","unstructured":"Pinto H, G\u00e1lvez R, Casanova J. Dermoscopy is the crucial step for proper outcome prospection when treating androgenetic alopecia with the Regenera\u00ae protocol: a score proposal. Int J Clin Dev Anat. 2018, 4:15-8. 10.11648\/j.ijcda.20180401.12","journal-title":"Int J Clin Dev Anat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2012.24.3.311","article-title":"Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study","volume":"24","author":"Han SH","year":"2012","unstructured":"Han SH, Byun JW, Lee WS, et al.. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol. 2012, 24:311-8. 10.5021\/ad.2012.24.3.311","journal-title":"Ann Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13324","article-title":"Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial","volume":"30","author":"Kanti V","year":"2016","unstructured":"Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. J Eur Acad Dermatol Venereol. 2016, 30:1183-9. 10.1111\/jdv.13324","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15171","article-title":"A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia","volume":"32","author":"Suchonwanit P","year":"2018","unstructured":"Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018, 32:2257-63. 10.1111\/jdv.15171","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S214907","article-title":"Minoxidil and its use in hair disorders: a review","volume":"13","author":"Suchonwanit P","year":"2019","unstructured":"Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019, 13:2777-86. 10.2147\/DDDT.S214907","journal-title":"Drug Des Devel Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics7020021","article-title":"Topical Minoxidil-loaded nanotechnology strategies for alopecia","volume":"7","author":"Santos AC","year":"2020","unstructured":"Santos AC, Pereira-Silva M, Guerra C, et al.. Topical Minoxidil-loaded nanotechnology strategies for alopecia. Cosmetics. 2020, 7:21. 10.3390\/cosmetics7020021","journal-title":"Cosmetics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.15570\/actaapa.2016.12","article-title":"Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction","volume":"25","author":"Hasanzadeh H","year":"2016","unstructured":"Hasanzadeh H, Nasrollahi SA, Halavati N, Saberi M, Firooz A. Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction. Acta Dermatovenerol Alp Pannonica Adriat. 2016, 25:41-4. 10.15570\/actaapa.2016.12","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"ref16","unstructured":"PubChem. Patent summary for US-2014234428-A1. (2013). Accessed: February 6, 2023: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-2014234428-A1."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124088","article-title":"A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men","volume":"47","author":"Olsen EA","year":"2002","unstructured":"Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002, 47:377-85. 10.1067\/mjd.2002.124088","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(87)70092-9","article-title":"Long-term efficacy of topical minoxidil in male pattern baldness","volume":"16","author":"Katz HI","year":"1987","unstructured":"Katz HI, Hien NT, Prawer SE, Goldman SJ. Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1987, 16:711-8. 10.1016\/s0190-9622(87)70092-9","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.06.014","article-title":"A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss","volume":"50","author":"Lucky AW","year":"2004","unstructured":"Lucky AW, Piacquadio DJ, Ditre CM, et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004, 50:541-53. 10.1016\/j.jaad.2003.06.014","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41681","article-title":"Real-world effectiveness, safety, and tolerability of cetosomal minoxidil 5% alone and a fixed drug combination of cetosomal minoxidil 5% with finasteride 0.1% in the management of androgenetic alopecia (Inbilt Study)","volume":"15","author":"Kerure A","year":"2023","unstructured":"Kerure A, Ghalla M, Mahajan S, Dhoot D, Barkate H. Real-world effectiveness, safety, and tolerability of cetosomal minoxidil 5% alone and a fixed drug combination of cetosomal minoxidil 5% with finasteride 0.1% in the management of androgenetic alopecia (Inbilt Study). Cureus. 2023, 15:e41681. 10.7759\/cureus.41681","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.042","article-title":"Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia","volume":"66","author":"Reid EE","year":"2012","unstructured":"Reid EE, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M, Wickless H. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012, 66:e97-102. 10.1016\/j.jaad.2010.11.042","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03030.x","article-title":"The psychosocial consequences of androgenetic alopecia: a review of the research literature","volume":"141","author":"Cash TF","year":"1999","unstructured":"Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999, 141:398-405. 10.1046\/j.1365-2133.1999.03030.x","journal-title":"Br J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04195.x","article-title":"Strategies of coping and quality of life in women with alopecia","volume":"144","author":"Schmidt S","year":"2001","unstructured":"Schmidt S, Fischer TW, Chren MM, Strauss BM, Elsner P. Strategies of coping and quality of life in women with alopecia. Br J Dermatol. 2001, 144:1038-43. 10.1046\/j.1365-2133.2001.04195.x","journal-title":"Br J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/188399-comparative-clinical-study-evaluating-the-efficacy-and-safety-of-topical-5-cetosomal-minoxidil-and-topical-5-alcohol-based-minoxidil-solutions-for-the-treatment-of-androgenetic-alopecia-in-indian-men","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:01Z","timestamp":1707509281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/188399-comparative-clinical-study-evaluating-the-efficacy-and-safety-of-topical-5-cetosomal-minoxidil-and-topical-5-alcohol-based-minoxidil-solutions-for-the-treatment-of-androgenetic-alopecia-in-indian-men"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.46568","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}